Blueprint Medicines Corp
BPMCDelisted Jul 18, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001597264
Blueprint Medicines Corp was delisted on Jul 18, 2025; its insiders filed their last Form 4 on Jul 21, 2025; 356 institutions reported holding it in 13F filings for Q2 2025, worth $8.65B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:39 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 16, 2022 | Feb 17, 2021 |
| Revenue | $508.8M | $249.4M | $204.0M | $180.1M | $793.7M |
| Cost of revenue | $20.2M | $8.54M | $17.8M | $17.9M | $425.0K |
| Research and development | $341.4M | $427.7M | $477.4M | $601.0M | $326.9M |
| Selling, general and administrative | $359.3M | $295.1M | $237.4M | $195.3M | $157.7M |
| Income tax | $1.23M | $968.0K | $5.24M | $3.00M | $1.06M |
| Net income | -$67.1M | -$507.0M | -$557.5M | -$644.1M | $313.9M |
| EPS, basic | $-1.07 | $-8.37 | $-9.35 | $-11.01 | $5.76 |
| EPS, diluted | $-1.07 | $-8.37 | $-9.35 | $-11.01 | $5.59 |
| Weighted shares, basic | 62.9M | 60.6M | 59.6M | 58.5M | 54.5M |
| Weighted shares, diluted | 62.9M | 60.6M | 59.6M | 58.5M | 56.2M |
| Margins and growth | |||||
| Net margin | -13.2% | -203.3% | -273.2% | -357.7% | 39.5% |
| Revenue growth, year over year | +104.0% | +22.2% | +13.3% | −77.3% | +1,093.4% |
| Net income growth, year over year | – | – | – | −305.2% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 16, 2022 | Feb 17, 2021 |
| Cash and equivalents | $102.0M | $71.3M | $119.7M | $209.9M | $684.6M |
| Accounts receivable | $75.8M | $42.8M | $23.5M | $25.2M | $7.10M |
| Inventory | $13.6M | $21.2M | $29.7M | $21.8M | $8.58M |
| Total current assets | $742.7M | $808.4M | $1.05B | $554.0M | $927.8M |
| Property, plant and equipment | $36.6M | $42.0M | $33.3M | $30.7M | $34.1M |
| Total assets | $1.18B | $1.05B | $1.35B | $1.25B | $1.72B |
| Accounts payable | $6.79M | $4.71M | $2.73M | $8.33M | $4.37M |
| Total current liabilities | $260.8M | $214.9M | $183.2M | $149.8M | $130.8M |
| Total liabilities | $881.1M | $918.6M | $835.2M | $281.5M | $248.3M |
| Shareholders' equity | $298.7M | $130.6M | $514.7M | $970.7M | $1.47B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 16, 2022 | Feb 17, 2021 |
| Operating cash flow | -$192.6M | -$436.8M | -$502.3M | -$298.7M | $387.0M |
| Capital expenditures | $4.63M | $16.1M | $8.92M | $3.09M | $3.16M |
| Free cash flow | -$197.2M | -$452.9M | -$511.2M | -$301.7M | $383.9M |
| Depreciation and amortization | $16.3M | $11.7M | $11.7M | $6.48M | $6.56M |
| Stock-based compensation | $108.9M | $92.7M | $99.0M | $91.6M | $75.5M |
| Investing cash flow | -$47.5M | $274.0M | -$149.5M | -$225.9M | -$434.2M |
| Financing cash flow | $273.1M | $119.2M | $561.8M | $50.7M | $617.8M |
| Net change in cash | – | – | -$90.0M | -$473.8M | $570.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 21.4% | 37.2% | 48.5% | 50.9% | 9.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 29, 2025 | 64.6M | +3.1% | SEC |
| Feb 11, 2025 | 63.9M | +4.4% | SEC |
| Oct 28, 2024 | 63.5M | +4.5% | SEC |
| Jul 30, 2024 | 63.3M | +4.4% | SEC |
| Apr 30, 2024 | 62.6M | +3.6% | SEC |
| Feb 13, 2024 | 61.2M | +2.1% | SEC |
| Oct 23, 2023 | 60.8M | +1.6% | SEC |
| Jul 28, 2023 | 60.7M | +1.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.